Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Santoni M, et al. Among authors: zucali pa. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. doi: 10.1007/s00262-023-03469-5. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37248424 Free PMC article.
Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL, Zucali PA. Ceresoli GL, et al. Among authors: zucali pa. Expert Opin Investig Drugs. 2012 Jun;21(6):833-44. doi: 10.1517/13543784.2012.681641. Epub 2012 Apr 23. Expert Opin Investig Drugs. 2012. PMID: 22519641 Review.
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C. Mencoboni M, et al. Oncol Res Treat. 2017;40(6):364-369. doi: 10.1159/000464410. Epub 2017 May 9. Oncol Res Treat. 2017. PMID: 28472807 Review.
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Giovannetti E, et al. Among authors: zucali pa. Mol Cancer Ther. 2010 Mar;9(3):581-93. doi: 10.1158/1535-7163.MCT-09-0665. Epub 2010 Feb 16. Mol Cancer Ther. 2010. PMID: 20159991 Free article.
164 results